"A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.

Sep 27, 2011, 09:15 ET from Aethlon Medical, Inc.

SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has released a white paper entitled: "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression."  The paper is available on the company's website at:

http://www.aethlonmedical.com/assets/001/5080.pdf

Or on SlideShare at:

http://www.slideshare.net/Aethlon/a-medical-device-to-inhibit-her2-breast-cancer

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ System provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C.  For more information, please visit www.aethlonmedical.com.

Certain of the statements herein or in the white paper referred to in this release may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier®, the Aethlon ADAPT™ System, or the HER2osome™ to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Hemopurifier®, the Aethlon ADAPT™ System, or the HER2osome™ as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier®, the Aethlon ADAPT™ System, or the HER2osome™ ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

SOURCE Aethlon Medical, Inc.



RELATED LINKS

http://www.aethlonmedical.com